REG - Hikma Pharmaceutical - Result of AGM

Hikma PharmaceuticalsAnnouncement

25/04/2022 15:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220425:nRSY2552Ja&default-theme=true

RNS Number : 2552J  Hikma Pharmaceuticals Plc  25 April 2022

 

Hikma Pharmaceuticals PLC

Results of 2022 Annual General Meeting

LONDON, 25 April 2022  Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai:
HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) announces its Annual General
Meeting ("AGM"), held at 1 New Burlington Place, W1S 2HR, London on 25 April
2022 commenced at 1:00 pm. Resolution 15 was withdrawn from the business of
the meeting and all the proposed resolutions were duly passed by shareholders
by way of a poll. Resolutions 1 to 14 were passed as ordinary resolutions and
Resolutions and 16 to 20 were passed as special resolutions.

The shareholder support for the re-election of the Chair of the Nomination and
Governance Committee (resolution 8) has reduced from circa 97% in 2021 to 69%
today. Following feedback from shareholders prior to the meeting, the Board
understands that this was due to the level of female representation on the
board falling to 22% as at the end of the AGM following the retirement of Dr.
Pamela Kirby.  The Board had envisaged that Dr. Kirby would step down in 2023
but understands that she wished to move on earlier than anticipated.  The
Board is in the process of reviewing candidates to raise the level of female
representation to meet or exceed its target of 33%.  The Board has noted the
recent announcement from the FCA regarding gender diversity and is taking
steps to ensure that these requirements are met within the established
timeframe.  The Board will provide an update on progress within six months of
the AGM and in the next annual report.

Copies of the resolutions dealing with special business passed at the AGM have
been submitted to the FCA's Electronic Submission System and will be available
from the National Storage Mechanism.

The total number of votes cast on the poll for each resolution (the full text
of the resolutions is detailed in the notice of the AGM dated 23 February
2022) is set out below. The number of Ordinary Shares in issue on 25 April
2022 was 239,588,352.  There were 12,833,233 Ordinary Shares held in
treasury, which are not counted in the voting capital of the Company which,
therefore, was 226,755,119.

 Resolution                                                                      Votes For    %       Votes Against  %      Total Cast   Withheld
 1. To receive the 2021 report and accounts                                      171,860,023  100.00  2              0.00   171,860,025  1,357,656
 2. To approve a final dividend of 36 cents per share                            173,183,661  99.98   37,842         0.02   173,221,503  1,083
 3. To re-appoint PricewaterhouseCoopers LLP as auditors                         172,098,319  99.35   1,121,992      0.65   173,220,311  2,275
 4.To authorise the Audit Committee to determine the auditors' remuneration      173,218,565  100.00  2,828          0.00   173,221,393  1,193
 5. To re-elect Said Darwazah as a director                                      161,582,905  94.37   9,648,531      5.63   171,231,436  1,991,150
 6. To re-elect Siggi Olafsson as a director                                     170,660,361  98.52   2,559,312      1.48   173,219,673  2,913
 7. To re-elect Mazen Darwazah as a director                                     149,941,788  86.59   23,211,478     13.41  173,153,266  69,320
 8. To re-elect Patrick Butler as a director                                     118,035,768  69.01   52,999,954     30.99  171,035,722  2,186,864
 9.To re-elect Ali Al-Husry as a director                                        169,733,613  98.03   3,418,717      1.97   173,152,330  70,256
 10. To re-elect John Castellani as a director                                   169,693,733  98.09   3,307,545      1.91   173,001,278  216,403
 11. To re-elect Nina Henderson as a director                                    153,383,051  88.55   19,832,207     11.45  173,215,258  2,423
 12. To re-elect Cynthia Flowers as a director                                   156,612,636  90.98   15,518,984     9.02   172,131,620  1,086,061
 13. To re-elect Douglas Hurt as a director                                      153,843,021  88.82   19,370,952     11.18  173,213,973  3,708
 14. To approve the remuneration report for the year ended 31 December 2021      157,785,532  91.09   15,426,369     8.91   173,211,901  5,780
 15. Withdrawn                                                                   -            -       -              -      -            -
 16. Authority to allot shares                                                   164,319,344  95.46   7,812,300      4.54   172,131,644  1,086,037
 17. To dis-apply pre-emption rights for general purposes                        172,966,280  99.86   248,712        0.14   173,214,992  2,689
 18. To dis-apply pre-emption rights for an acquisition or other capital         171,406,211  98.96   1,809,187      1.04   173,215,398  2,283
 investment
 19. To authorise the Company to purchase its own shares                         171,959,574  99.36   1,107,248      0.64   173,066,822  155,764
 20. To authorise the Company to hold general meetings on no less than 14 clear  152,971,808  88.31   20,249,569     11.69  173,221,377  1,209
 days' notice

 

Declaration of final dividend

The dividend of 36 cents per share will be paid on 28 April 2022 to
shareholders on the register on 18 March 2022.  Shareholders who are not
resident in Jordan have been given the option of receiving their dividend in
Pounds Sterling.  The exchange rate in respect of this dividend will be
$1.3021 to £1. The exchange rate for Jordanian Dinar is fixed to the US
Dollar at circa $1 to 0.709JD.

- ENDS -

Enquiries:

 

 Hikma Pharmaceuticals PLC
 Peter Speirs                                 +44 20 7399 2670

 Company Secretary

 Susan Ringdal                                +44 20 7399 2670

 EVP, Strategic Planning and Global Affairs

 

 

 

 

About Hikma

Hikma helps put better health within reach every day for millions of people in
more than 50 countries around the world. For more than 40 years, we've been
creating high-quality medicines and making them accessible to the people who
need them. Headquartered in the UK, we are a global company with a local
presence across the United States (US), the Middle East and North Africa
(MENA) and Europe, and we use our unique insight and expertise to transform
cutting-edge science into innovative solutions that transform people's lives.
We're committed to our customers, and the people they care for, and by
thinking creatively and acting practically, we provide them with a broad range
of branded and non-branded generic medicines. Together, our 8,600 colleagues
are helping to shape a healthier world that enriches all our communities. We
are a leading licensing partner, and through our venture capital arm, are
helping bring innovative health technologies to people around the world. For
more information, please visit: www.hikma.com
(https://nam04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2531421-1%26h%3D3823969217%26u%3Dhttp%253A%252F%252Fwww.hikma.com%252F%26a%3Dwww.hikma.com&data=02%7C01%7Cmellisa%40hikma.uk.com%7C997d2fa3727b41845d4308d7ecef5a5f%7C178c1a723d3c40afbaa754615303bcdc%7C0%7C0%7C637238385059390461&sdata=JoY1dcOqWcUS12nfDFqq49wlYgBsw3%2BZFmrlDQ4QNI0%3D&reserved=0)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGSEUFLIEESEDL